zasocitinib
Small moleculeexperimental
Clinical trial activity
23 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
16
Phase 3
9
Phase 4
0
Earliest trial started Aug 18, 2021 (NCT04999839)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase TYK2INHIBITOR
TYK2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CNc1cc(Nc2cccn(-c3ccccn3)c2=O)nc2c(C(=O)N[C@@H]3CC[C@H]3OC)cnn12- Mol. weight
- 460.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314423 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07286058 | Phase 3 | Feb 27, 2026 | Takeda |
| NCT07244263 | Phase 2 | Feb 6, 2026 | Takeda |
| NCT07250802 | Phase 3 | Dec 1, 2025 | Takeda |
| NCT07108283 | Phase 2 | Nov 3, 2025 | Takeda |
| NCT06973291 | Phase 3 | Jul 9, 2025 | Takeda |
| NCT06764615 | Phase 2 | Apr 29, 2025 | Takeda |
| NCT06671496 | Phase 3 | Mar 6, 2025 | Takeda |
| NCT06671483 | Phase 3 | Mar 3, 2025 | Takeda |
| NCT06793943 | Phase 1 | Jan 23, 2025 | Takeda |
| NCT06550076 | Phase 3 | Sep 4, 2024 | Takeda |
| NCT06111547 | Phase 1 | May 30, 2024 | Takeda |
| NCT06258265 | Phase 1 | Apr 29, 2024 | Takeda |
| NCT06290050 | Phase 1 | Mar 29, 2024 | Takeda |
| NCT06254950 | Phase 2 | Mar 29, 2024 | Takeda |
| NCT06323356 | Phase 3 | Mar 19, 2024 | Takeda |
| NCT06233461 | Phase 2 | Mar 5, 2024 | Takeda |
| NCT06088043 | Phase 3 | Nov 6, 2023 | Takeda |
| NCT06108544 | Phase 3 | Nov 6, 2023 | Takeda |
| NCT05992155 | Phase 1 | Sep 27, 2023 | Takeda |
| NCT05976321 | Phase 1 | Sep 22, 2023 | Takeda |
Showing 20 of 23 trials
Page 1 / 2
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 21 | 21 | 3 | 2023 |
| Nimbus Apollo | For profit | 2 | 2 | 1 | 2021 |
| Innovaderm | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1